Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvon Protection Regulatory News (AVON)

Share Price Information for Avon Protection (AVON)

Share Price is delayed by 15 minutes
Get Live Data
1,756.00    16.00 (0.92%)
Bid:
1,780.00
Ask:
1,784.00
Spread: 4.00 (0.225%)
Market Cap: £517.17m
AVON Live PriceLast checked at - London Stock Exchange

Intraday Avon Protection Share Chart

Post Close Trading Update

13 Oct 2021 07:00

RNS Number : 8651O
Avon Protection PLC
13 October 2021
 

13 October 2021

Avon Protection plc

Post Close Trading Update

 

Avon Protection plc ("Avon" or the "Group") today provides the following post close trading update for its financial year ended 30 September 2021 ("FY21").

 

Trading update

Avon has continued to see good commercial momentum in the second half of FY21, with order intake for the year of c.$280 million. This represents total year-on-year order growth of 34% and growth of 15% excluding Team Wendy. As a result, the Group has carried a strong closing order book of $141 million into the new financial year ("FY22"), up 39% on 30 September 2020. This momentum underpins confidence in the Group's growth expectations for FY22.

 

The Group expects to report revenue of $250 million for FY21 (2020: $213.6 million), which is within the range indicated in our trading update of 13 August 2021. This includes a Team Wendy contribution of $41 million from the first 11 months of ownership, in line with expectations at the time of acquisition.

 

As expected, we have seen revenue growth in our First Responder business and Military respiratory portfolio, offset by declines in Military ballistic revenue due to the previously announced delays. Overall, Military revenue is expected to decline by 3% to $149 million with respiratory revenue growth of 10% being offset by a 31% decline in Military ballistic revenues. First Responder revenues are expected to have increased by 2% to $61 million, against a strong comparator in 2020, driven by very encouraging growth in our ballistic protection portfolio.

 

Trading profitability in the remainder of FY21 was in line with the expectations set out in the August trading update. The Group will however recognise one-off, non-cash, ballistic protection inventory adjustments, which are expected to reduce the reported adjusted EBITDA margin for FY21 to between 15% and 16%.

 

Cash conversion has come through more strongly than anticipated at the time of the August trading update. As a result, we expect FY21 reported cash conversion of c.80% and net debt before lease liabilities of $27 million at 30 September 2021.

 

Commenting, Paul McDonald, Chief Executive Officer, said:

"We have made considerable commercial progress over the last 12 months in continuing to build a broader portfolio of contracts, increasing our pipeline of opportunities and making record levels of investment in the business.

 

We carry significant commercial momentum into FY22, which will also benefit from a strong ramp-up in body armor, as well as the strengthened senior management, processes and infrastructure we have put in place over the past year whilst navigating the ongoing disruption related to Covid through our supply chains.

 

We remain well set for growth in FY22 and beyond and are as confident as ever about the medium-term prospects of Avon Protection. This is underpinned by a strong order book, a growing and visible contract pipeline and our global market leading positions in respiratory and ballistic protection."

 

Notice of Results

The Group will release its results for the year ended 30 September 2021 on 23 November 2021.

 

For further enquiries, please contact:

 

Avon Protection plc

Paul McDonald, Chief Executive Officer

01225 896 848

Nick Keveth, Chief Financial Officer

Rachel Stevens, Director of Investor Relations

MHP Communications

Andrew Jaques

0203 128 8570

Charlie Barker

avonprotection@mhpc.com

Pete Lambie

 

Legal Entity Identifier: 213800JM1AN62REBWA71

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

Note to editors: 

Avon Protection plc is listed on the London Stock Exchange (LSE: AVON) and is an innovative technology group, which designs and produces life critical personal protection systems to maximise the performance and capabilities of its customers, with leading positions in the respiratory and ballistic protection markets for the world's militaries and first responders.

For further information, please visit our website www.avon-protection-plc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFETIDLFLIL
Date   Source Headline
3rd Jun 20256:00 pmRNSRenewi
29th May 202510:00 amRNSHolding(s) in Company
21st May 20257:00 amRNSInterim Results
20th May 20254:00 pmRNSNotification of change in particulars of director
16th May 20253:00 pmRNSNotification of change in particulars of director
15th May 20251:00 pmRNSHolding(s) in Company
7th May 202510:00 amRNSDirectors'/PDMR Shareholding
6th May 202512:00 pmRNS-RNotice of Results & Investor Presentation via IMC
11th Apr 20254:00 pmRNSHolding(s) in Company
8th Apr 202511:00 amRNSDirectors'/PDMR Shareholding
27th Mar 20252:00 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSQ2 trading update
20th Mar 202510:00 amRNSHolding(s) in Company
11th Mar 20255:00 pmRNSDirector/PDMR Shareholding
6th Mar 20253:00 pmRNSDirectors'/PDMR Shareholdings
4th Mar 20254:00 pmRNSHolding(s) in Company
3rd Mar 20257:00 amRNSNext Generation IHPS Delivery Order
14th Feb 20252:00 pmRNSDirectors'/PDMR Shareholding
11th Feb 20254:00 pmRNSHolding(s) in Company
7th Feb 20254:00 pmRNSFinal Dividend Currency Exchange Rate
5th Feb 20254:00 pmRNSDirectors'/PDMR Shareholdings
31st Jan 202512:00 pmRNSResult of AGM
31st Jan 20257:00 amRNSAGM Statement
27th Jan 20253:00 pmRNSHolding(s) in Company
9th Jan 20257:00 amRNSThales UK Contract Renewal
7th Jan 20259:00 amRNSDirectors'/PDMR Shareholding
6th Jan 20257:00 amRNSNext Generation IHPS Delivery Order
12th Dec 20242:00 pmRNSHolding in Company
10th Dec 20249:00 amRNSNotice of Annual Report & Accounts and AGM 2025
6th Dec 202411:00 amRNSDirectors'/PDMR Shareholding
28th Nov 20245:00 pmRNSDirector/PDMR Shareholding
19th Nov 20242:00 pmRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSPreliminary Results
6th Nov 20242:00 pmRNSHolding in Company
6th Nov 202410:00 amRNSDirectors'/PDMR Shareholding
25th Oct 202411:05 amRNSAppointment of Joint Corporate Broker
22nd Oct 20247:00 amRNSNotice of Results
8th Oct 202410:00 amRNSDirectors'/PDMR Shareholding
2nd Oct 20243:05 pmRNSHolding(s) in Company
26th Sep 20246:05 pmRNSHolding(s) in Company
10th Sep 20243:30 pmRNSDirector/PDMR Shareholding
15th Aug 20247:00 amRNSInterim Dividend Currency Exchange Rate
7th Aug 20249:00 amRNSDirectors'/PDMR Shareholdings
1st Aug 20248:19 amRNSChange of Company Name
1st Aug 20247:00 amRNSHolding(s) in Company
29th Jul 202412:00 pmRNSPDMR Shareholdings
25th Jul 20247:00 amRNSNew delivery order & updated FY 2024 guidance
10th Jul 20249:00 amRNSNotification of transaction of PDMR
8th Jul 202412:00 pmRNSDirectors'/PDMR Shareholdings
6th Jun 20243:00 pmRNSDirectors'/PDMR Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.